Overall, the mean affected BSA decreased from 13.3% to 1.1% (Figure 4A), and the mean PGA decreased from 3.0 to 0.9 (Figure 4B), demonstrating that up to 12 months of biologic therapy improved psoriasis severity on average from “moderate†to “almost clear†in the pooled population. Similarly, there was a pronounced improvement in the overall mean composite BSA×PGA score (Figure 4C).
Improvements in disease severity outcomes were also observed in all subgroup analyses (Figure 1). Bio-naïve and bio-experienced patients showed comparable improvements in psoriasis severity (Figure 1, top); both subgroups exhibited robust decreases in their mean BSA, PGA, and composite BSA×PGA scores from baseline to follow-up.
